CYP2C9 and myopathy: Variants in <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> were combined into a functional PGx burden score, and their associations with statin regimen modification, intolerance, myopathy, liver injury, adherence, and composite adverse events were evaluated.